These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 31413089)

  • 1. Emerging disease-modifying therapies for sickle cell disease.
    Carden MA; Little J
    Haematologica; 2019 Sep; 104(9):1710-1719. PubMed ID: 31413089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Treatment of Sickle Cell Disease.
    Kapoor S; Little JA; Pecker LH
    Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sickle cell disease in the new era: advances in drug treatment.
    Lee MT; Ogu UO
    Transfus Apher Sci; 2022 Oct; 61(5):103555. PubMed ID: 36096995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.
    Telen MJ
    Blood; 2016 Feb; 127(7):810-9. PubMed ID: 26758919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Options for Sickle Cell Disease.
    Meier ER
    Pediatr Clin North Am; 2018 Jun; 65(3):427-443. PubMed ID: 29803275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment.
    Piccin A; Murphy C; Eakins E; Rondinelli MB; Daves M; Vecchiato C; Wolf D; Mc Mahon C; Smith OP
    Eur J Haematol; 2019 Apr; 102(4):319-330. PubMed ID: 30664257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sickle cell disease: current treatment and emerging therapies.
    Neumayr LD; Hoppe CC; Brown C
    Am J Manag Care; 2019 Nov; 25(18 Suppl):S335-S343. PubMed ID: 31809007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials.
    Ali MA; Ahmad A; Chaudry H; Aiman W; Aamir S; Anwar MY; Khan A
    Exp Hematol; 2020 Dec; 92():11-18.e1. PubMed ID: 32841705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting sickle cell disease root-cause pathophysiology with small molecules.
    Saunthararajah Y
    Haematologica; 2019 Sep; 104(9):1720-1730. PubMed ID: 31399526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging treatments for sickle cell disease.
    Monus T; Howell CM
    JAAPA; 2019 Sep; 32(9):1-5. PubMed ID: 31460979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sickle cell disease: progress towards combination drug therapy.
    Pace BS; Starlard-Davenport A; Kutlar A
    Br J Haematol; 2021 Jul; 194(2):240-251. PubMed ID: 33471938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease.
    Bhatt S; Argueta DA; Gupta K; Kundu S
    Antioxid Redox Signal; 2024 Jun; 40(16-18):1025-1049. PubMed ID: 37975291
    [No Abstract]   [Full Text] [Related]  

  • 17. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sickle Cell Disease: A Primer for Primary Care Providers.
    Kimrey S; Saving KL
    Pediatr Ann; 2020 Jan; 49(1):e43-e49. PubMed ID: 31930422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathophysiology and treatment of sickle-cell disease].
    van Beers EJ; Peters M; Biemond BJ
    Ned Tijdschr Geneeskd; 2005 May; 149(21):1144-9. PubMed ID: 15940917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.